CGTLive®’s Weekly Rewind – June 20, 2025
Review top news and interview highlights from the week ending June 20, 2025.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Second Patient Dies Following Treatment With Sarepta’s DMD Gene Therapy Elevidys
In light of the patient’s death, Sarepta put a temporary hold on shipments of Elevidys for patients who are nonambulatory.
2. Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, on CAR-T Therapy JNJ-90014496's Safety Profile in R/R LBCL
The associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial for the CD19/CD20–directed bispecific CAR-T.
3. Beam’s Base-Editing HSC Therapy BEAM-101 Raises HbF Levels in Patients With Sickle Cell Disease
Beam Therapeutics’ team provided insight on data the company presented at EHA's 2025 Congress.
4. Omotayo Fasan, MRCP, DTM&H, MBBS, on Evaluating CAR-T GLPG5101 in R/R NHL
The head of the clinical development program at Galapagos discussed the design of GLPG5101 and touched on future plans for the therapy and other cell therapy products in the company's pipeline.
5. Alzheimer's & Brain Awareness Month 2025: Looking Back at Recent Progress in Cell and Gene Therapy
In honor of Alzheimer's & Brain Awareness Month, observed annually in June, we took a look back at recent news and insights in cell and gene therapy for Alzheimer disease and other dementias.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.
